Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABT-493/ABT-530 for chronic hepatitis C virus genotype 2 infection has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Virus (HCV) Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-09-18